Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 16, 2014, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $63.36 to $15,595,781.10.

Highlighted Stocks Traded by Insiders:

Metro Bancorp (METR) - FREE Research Report

Gelder Douglas S, who is Director at Metro Bancorp, sold 2,826 shares at $24.85 on Dec. 16, 2014. Following this transaction, the Director owned 116,625 shares meaning that the stake was reduced by 2.37% with the 2,826-share transaction.

The shares most recently traded at $24.88, up $0.03, or 0.11% since the insider transaction. Historical insider transactions for Metro Bancorp go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 6,260
  • 12-Week # shares bought: 1,100
  • 12-Week # shares sold: 6,260
  • 24-Week # shares bought: 1,100
  • 24-Week # shares sold: 6,260

The average volume for Metro Bancorp has been 29,800 shares per day over the past 30 days. Metro Bancorp has a market cap of $349.3 million and is part of the financial sector and banking industry. Shares are up 14.16% year-to-date as of the close of trading on Monday.

Metro Bancorp, Inc. operates as the bank holding company for Metro Bank, which provides retail and commercial banking services for consumers, and small and mid-sized companies in Pennsylvania. The company has a P/E ratio of 17.4. Currently, there are no analysts who rate Metro Bancorp a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on METR - FREE

TheStreet Quant Ratings rates Metro Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, solid stock price performance, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Metro Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Farmer Ronald Harold, who is Director at Valeant Pharmaceuticals International, bought 500 shares at $160.48 on Dec. 16, 2014. Following this transaction, the Director owned 33,004 shares meaning that the stake was boosted by 1.54% with the 500-share transaction.

The shares most recently traded at $136.92, down $23.56, or 17.21% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 10,000

The average volume for Valeant Pharmaceuticals International has been 2.6 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $46.6 billion and is part of the health care sector and drugs industry. Shares are up 17.68% year-to-date as of the close of trading on Monday.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. The company has a P/E ratio of 90.1. Currently, there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Eagle Bancorp (EGBN) - FREE Research Report

Summers David Preston, who is Director at Eagle Bancorp, sold 5,000 shares at $34.62 on Dec. 16, 2014. Following this transaction, the Director owned 22,872 shares meaning that the stake was reduced by 17.94% with the 5,000-share transaction.

The shares most recently traded at $34.98, up $0.36, or 1.02% since the insider transaction. Historical insider transactions for Eagle Bancorp go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 49,876
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 49,876
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 50,776

The average volume for Eagle Bancorp has been 78,400 shares per day over the past 30 days. Eagle Bancorp has a market cap of $890.1 million and is part of the financial sector and banking industry. Shares are up 13.42% year-to-date as of the close of trading on Monday.

Eagle Bancorp, Inc. operates as a bank holding company for EagleBank that provides commercial and consumer banking services in the United States. The company has a P/E ratio of 17.8. Currently, there are 3 analysts who rate Eagle Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGBN - FREE

TheStreet Quant Ratings rates Eagle Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in stock price during the past year, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eagle Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null